232 related articles for article (PubMed ID: 19368894)
21. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
[TBL] [Abstract][Full Text] [Related]
22. Structure of C3b in complex with CRIg gives insights into regulation of complement activation.
Wiesmann C; Katschke KJ; Yin J; Helmy KY; Steffek M; Fairbrother WJ; McCallum SA; Embuscado L; DeForge L; Hass PE; van Lookeren Campagne M
Nature; 2006 Nov; 444(7116):217-20. PubMed ID: 17051150
[TBL] [Abstract][Full Text] [Related]
23. Diversity in the C3b [corrected] contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family.
Garcia BL; Summers BJ; Lin Z; Ramyar KX; Ricklin D; Kamath DV; Fu ZQ; Lambris JD; Geisbrecht BV
J Biol Chem; 2012 Jan; 287(1):628-640. PubMed ID: 22086928
[TBL] [Abstract][Full Text] [Related]
24. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Vogel CW; Fritzinger DC
Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
[TBL] [Abstract][Full Text] [Related]
25. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
Kozlov LV; Soliakov LS; Zinchenko AA
Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
[TBL] [Abstract][Full Text] [Related]
26. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
27. Structural studies on the cobra venom factor: isolation, purification, crystallization and preliminary crystallographic analysis.
Sharma S; Jabeen T; Singh RK; Bredhorst R; Vogel CW; Betzel C; Singh TP
Acta Crystallogr D Biol Crystallogr; 2001 Apr; 57(Pt 4):596-8. PubMed ID: 11264593
[TBL] [Abstract][Full Text] [Related]
28. Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.
Katschke KJ; Stawicki S; Yin J; Steffek M; Xi H; Sturgeon L; Hass PE; Loyet KM; Deforge L; Wu Y; van Lookeren Campagne M; Wiesmann C
J Biol Chem; 2009 Apr; 284(16):10473-9. PubMed ID: 19196712
[TBL] [Abstract][Full Text] [Related]
29. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus.
Rehana S; Manjunatha Kini R
Toxicon; 2007 Jul; 50(1):32-52. PubMed ID: 17412383
[TBL] [Abstract][Full Text] [Related]
30. The structure of complement C3b provides insights into complement activation and regulation.
Abdul Ajees A; Gunasekaran K; Volanakis JE; Narayana SV; Kotwal GJ; Murthy HM
Nature; 2006 Nov; 444(7116):221-5. PubMed ID: 17051152
[TBL] [Abstract][Full Text] [Related]
31. Distal recognition site for classical pathway convertase located in the C345C/netrin module of complement component C5.
Sandoval A; Ai R; Ostresh JM; Ogata RT
J Immunol; 2000 Jul; 165(2):1066-73. PubMed ID: 10878385
[TBL] [Abstract][Full Text] [Related]
32. Formation of high-affinity C5 convertases of the alternative pathway of complement.
Rawal N; Pangburn M
J Immunol; 2001 Feb; 166(4):2635-42. PubMed ID: 11160326
[TBL] [Abstract][Full Text] [Related]
33. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
34. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
35. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
36. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
Kinoshita T; Dodds AW; Law SK; Inoue K
Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
[TBL] [Abstract][Full Text] [Related]
37. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
[TBL] [Abstract][Full Text] [Related]
38. A cobra venom factor (CVF)-induced C3 convertase activity in the hemolymph of Galleria mellonella.
Phipps D; Menger M; Chadwick JS; Aston WP
Dev Comp Immunol; 1987; 11(1):37-46. PubMed ID: 3647909
[TBL] [Abstract][Full Text] [Related]
39. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
40. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor.
O'Keefe MC; Caporale LH; Vogel CW
J Biol Chem; 1988 Sep; 263(25):12690-7. PubMed ID: 3045125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
